Speakers

Expand/Collapse

You-Yeon Won
Chief Scientific Officer
Spirrow Therapeutics

Day Two

Thursday – July 15, 2021

2:30 pm | Polymer Lung Surfactant: A First-in-Kind Synthetic Surfactant Therapeutic for ARDS

Mark Andrew Borden
Director, Biomedical Engineering
Respirogen

Day Two

Thursday – July 15, 2021

3:00 pm | Respirogen Oxygen Microbubble Therapy in ARDS

Oren Hershkovitz
Chief Executive Officer
Enlivex

Day Two

Thursday – July 15, 2021

3:30 pm | Allocetra, a Novel Macrophage Reprogramming Cell Therapy Being Developed for the Treatment of Inflammatory Diseases Including Sepsis, COVID-19 and ARDS

Eric Jenkins
Senior Medical Director
Athersys

Day One

Wednesday – July 14, 2021

9:00 am | Panel Discussion: Deep Diving into the Failures of COVID-19 Related ARDS Clinical Trials to Learn How to Avoid Common Mistakes & Streamline the Development of Clinically Effective Therapeutics for COVID-19 ARDS

Day Two

Thursday – July 15, 2021

2:00 pm | Blinded by the Light: Looking Past Mortality to Negotiate Clinically Relevant and Achievable ARDS Trial Endpoints

Melanie Kelly
Chief Scientific Officer
Tetra Biopharma

Day Two

Thursday – July 15, 2021

9:00 am | Development of Novel Injectable and Inhaled Cannabinoid Drugs for Systemic Inflammation and ARDS

Nina Patel
Director, Clinical Development & Medical Affairs ILD
Boehringer Ingelheim

Shamsah Kazani
Senior Medical Director
Alexion Pharmaceuticals

Natacha Le Moan
Senior Director - Translational Research
Catalyst Biosciences

Tim Higenbottam
President
Faculty of Pharmaceutical Medicine

Day One

Wednesday – July 14, 2021

9:00 am | Panel Discussion: Deep Diving into the Failures of COVID-19 Related ARDS Clinical Trials to Learn How to Avoid Common Mistakes & Streamline the Development of Clinically Effective Therapeutics for COVID-19 ARDS

8:00 am | Outlining How the Pandemic Has Transformed the ARDS Drug Development Landscape & Contextualising Key Updates in ARDS Drug Development Over the Past 12 Months

Brijesh Patel
Clinical Senior Lecturer in Cardiothoracic
Imperial College London

Day One

Wednesday – July 14, 2021

9:00 am | Panel Discussion: Deep Diving into the Failures of COVID-19 Related ARDS Clinical Trials to Learn How to Avoid Common Mistakes & Streamline the Development of Clinically Effective Therapeutics for COVID-19 ARDS

8:30 am | Analyzing the Pathology & Molecular Mechanisms Behind COVID-19 Associated ARDS to Determine Which Indicators Best Predict Onset of Severe ARDS & COVID-19 Pneumonia

David Thickett
Professor of Respiratory Medicine
University of Birmingham

Day One

Wednesday – July 14, 2021

10:30 am | Translating Lessons Learned From COVID-19 Associated ARDS to Non-COVID-19 Associated ARDS: Leveraging the Latest Research to Strategize Drug Development Against ARDS

Pablo Pelegrin
Scientific Deputy Director & Principal Investigator
Biomedical Research Institute of Murcia

Day One

Wednesday – July 14, 2021

11:30 am | Molecular Mechanisms of the ARDS Inflammatory Response in COVID-19 for Drug Development

Joe Garcia
Chief Executive Officer
Aqua Lung Therapeutics

Day One

Wednesday – July 14, 2021

1:30 pm | DAMPening ARDS & VILI Inflammation with a Novel Biologic Targeting eNAMPT

Kenneth Adler
Professor
Biomarck Pharmaceuticals

Day One

Wednesday – July 14, 2021

2:00 pm | An Inhaled Inhibitor of MARCKS Improved Oxygenation & Reduced Mortality in ARDS Patients

Jessie Huang
Post-Doctoral Associate
Boston University

Day Two

Thursday – July 15, 2021

9:30 am | Investigating Stem Cell-Based Modelling for Understanding COVID-19 Pathogenesis & Therapeutics

Danny McAuley
Clinical Professor
Queens University Belfast

Day Two

Thursday – July 15, 2021

10:00 am | Deep Diving into Modelling for ARDS: Using Human Models to Predict the Pathophysiology of ARDS in COVID-19/None COVID-19 Patients & Accelerate Drug Development

Juho Jalkanen
Vice President Business Development
Faron Pharmaceuticals

Day Two

Thursday – July 15, 2021

1:30 pm | Designing & Developing ARDS Clinical Trials From Concept to Clinic: Understanding What Parameters You Must Consider to Optimize the Success of Your Therapeutic in a Clinical Setting

Seung-Yong Seong
Co-Chief Executive Officer
Shaperon

Day Two

Thursday – July 15, 2021

12:00 pm | Damage-Associated Molecular Pattern (DAMPs) for ARDS by COVID-19: From the Basic Immunology to Phase 2 Clinical Trial

Miguel Forte
Chief Executive Officer
Bone Therapeutics

Day One

Wednesday – July 14, 2021

7:55 am | Chair’s Opening Remarks

Anthony Ting
Vice President of Regenerative Medicine & Head of Cardiopulmonary Programs
Athersys

Day Two

Thursday – July 15, 2021

8:55 am | Chair’s Opening Remarks

Bernhard Fischer
Chief Executive Officer
Apeptico

Day One

Wednesday – July 14, 2021

3:30 pm | A Novel Targeted Inhaled Therapy for Treatment of ARDS by Reducing Extravascular Lung Water

Marcelo Hill
Chief Scientific Officer
ARDAN Pharma

Day One

Wednesday – July 14, 2021

12:00 pm | Targeting Inflammasomes to Control Coronavirus-Induced T cell Dysfunction

Harry Karmouty
Assistant Professor
Tenure Track at The University of Texas Health Science Center at Houston (UTHealth)

Day One

Wednesday – July 14, 2021

11:00 am | Elevated Hyaluronan in ARDS Associated With COVID-19

Aprile Pilon
President & Chief Executive Officer
Trove Therapeutics

Day One

Wednesday – July 14, 2021

4:30 pm | Therabron (rhCC10 protein): A Host-Targeted Multi-Modal Therapy to Prevent and Treat ARDS

Ritu Lal
Chief Executive Officer
GEn1E Lifesciences

Day One

Wednesday – July 14, 2021

5:00 pm | GEn1E Lifesciences: A Platform for Advancing Treatments for Rare Inflammatory Diseases

Racheli Ofir
Vice President - Research & IP
Pluristem Therapeutics

Day One

Wednesday – July 14, 2021

4:00 pm | Evaluating the Risk Reward Profile of Cell Therapies for ARDS and Understanding How They Can be Utilized to Positively Influence Recovery/Mortality in ARDS Patients